8-K: Achieve Life Sciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Achieve Life Sciences reported its third quarter 2024 financial results, completed enrollment in a key clinical trial, and received Breakthrough Therapy designation from the FDA for its vaping cessation treatment.

Summary

• Achieve Life Sciences announced its financial results for the third quarter of 2024, reporting a net loss of $12.5 million for the quarter and $27.5 million for the nine-month period ending September 30, 2024.
• The company's cash, cash equivalents, restricted cash, and short-term investments totaled $42.9 million as of September 30, 2024.
• Operating expenses were $12.5 million for the quarter and $26.9 million for the nine-month period.
• Achieve completed enrollment in the Phase 3 ORCA-OL clinical trial with 479 participants across 29 U.S. sites, evaluating the long-term safety of cytisinicline for smoking and vaping cessation.
• The Data Safety Monitoring Committee for the ORCA-OL trial found no safety concerns and allowed the study to proceed as planned.
• The FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette cessation in July.
• Achieve has appointed Richard Stewart as CEO and Thomas King as Executive Chairman, and formed a U.S. product launch team.
• The company plans to submit a New Drug Application (NDA) in the second quarter of 2025.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting clinical trial progress, regulatory achievements, and leadership changes, but also acknowledges financial losses typical for a company at this stage.

Positives

• The successful completion of enrollment in the ORCA-OL trial indicates progress in the development of cytisinicline.
• The Breakthrough Therapy designation from the FDA could expedite the approval process for cytisinicline as a vaping cessation treatment.
• The appointment of experienced leaders like Richard Stewart and Thomas King strengthens the management team.
• The formation of a dedicated U.S. product launch team demonstrates the company's commitment to commercialization.
• The company has a solid cash position of $42.9 million.

Negatives

• The company reported a net loss of $12.5 million for the third quarter of 2024 and $27.5 million for the nine-month period.
• Operating expenses were $12.5 million for the quarter and $26.9 million for the nine-month period.

Risks

• The company's future success depends on the successful development and commercialization of cytisinicline.
• Achieve may not be able to obtain additional financing to fund the development and commercialization of cytisinicline.
• There is a risk that cytisinicline will not receive regulatory approval or be successfully commercialized.
• New developments in the smoking cessation landscape could require changes in business strategy or clinical development plans.
• The company's intellectual property may not be adequately protected.

Future Outlook

Achieve plans to submit a New Drug Application (NDA) for cytisinicline in the second quarter of 2025 and is focused on commercial launch preparedness.

Management Comments

• Rick Stewart, Chief Executive Officer of Achieve, stated that the company remains focused on advancing cytisinicline to address the need for effective smoking and vaping cessation solutions.
• Rick Stewart also mentioned that the company is committed to bringing the first new prescription therapy to market in over 20 years.

Industry Context

The announcement comes amid increased attention on nicotine dependence and a lack of innovation in smoking cessation treatments, positioning Achieve's cytisinicline as a potential first-in-class therapy.

Comparison to Industry Standards

• The completion of enrollment in the ORCA-OL trial is a significant milestone, comparable to other late-stage pharmaceutical companies advancing similar treatments.
• The Breakthrough Therapy designation from the FDA is a positive signal, similar to other companies that have received this designation for promising therapies.
• The company's cash position of $42.9 million is adequate for a company at this stage of development, but will likely require further capital raises to fund the NDA submission and commercialization.
• The reported net loss is typical for a clinical-stage pharmaceutical company that is investing heavily in research and development.

Management Changes

Stakeholder Impact

• Shareholders may view the clinical trial progress and regulatory achievements positively.
• Employees may be impacted by the leadership changes and the formation of the U.S. product launch team.
• Customers (potential patients) may benefit from the development of a new treatment for nicotine dependence.
• The company's suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• Achieve will continue to analyze data from the ORCA-OL clinical trial.
• The company will prepare for the submission of the New Drug Application (NDA) in the second quarter of 2025.
• The U.S. product launch preparedness team will continue to execute activities in preparation for cytisinicline entry to the U.S. market.

Key Dates

Keywords

cytisinicline, nicotine dependence, smoking cessation, vaping cessation, clinical trial, FDA, Breakthrough Therapy, pharmaceutical, ORCA-OL, NDA